Posts

Posted on

BigCommerce Announces Pricing of Follow-on Public Offering

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — BigCommerce Holdings, Inc. (“BigCommerce” or the “Company”) (Nasdaq: BIGC) today announced the pricing of its previously announced follow-on public offering of its Series 1 common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) at a price to the public of $68.00 per share. BigCommerce is offering 1,000,000 shares of its Series 1 common stock and the selling stockholders named in the registration statement, including certain members of management and entities affiliated with directors of the Company, are offering 4,000,000 shares of the Company’s Series 1 common stock. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of the Company’s Series 1 common stock at the public offering price. The Company will not receive any proceeds from the sale of the shares by the selling stockholders. The offering is expected to close on November 17, 2020, subject to customary closing conditions.

J.P. Morgan and Barclays are serving as lead book-running managers for the proposed offering. Morgan Stanley, Jefferies and KeyBanc Capital Markets are acting as book-running managers. Canaccord Genuity, Needham & Company, Piper Sandler, Raymond James, Stifel and Truist Securities are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the SEC on November 12, 2020. The offering is being made only by means of a prospectus. A copy of the prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847 or by email at [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BigCommerce

BigCommerce is a leading software-as-a-service (SaaS) ecommerce platform that simplifies the creation of beautiful, engaging online stores by delivering a unique combination of ease-of-use, enterprise functionality, and flexibility. BigCommerce powers both our customers’ branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. As of September 30, 2020, BigCommerce served approximately 60,000 online stores across industries in approximately 150 countries, including Ben & Jerry’s, Skullcandy, Sony, and Woolrich. Headquartered in Austin, BigCommerce has offices in San Francisco, Sydney, and London.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. Forward-looking statements in this release include, but are not limited to, statements concerning the completion, timing and size of the proposed public offering. The Company’s expectations and beliefs regarding these matters may not materialize and could change, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in the Company’s filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as well as any other future annual, quarterly and current reports that it files with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to BigCommerce at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. BigCommerce assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Media Relations Contact

Rachael Hensley
[email protected]
ICR PR for BigCommerce
[email protected]

Investor Relations Contact

Rohit Giri
[email protected]



Posted on

triBalance Completes First FX SA-CCR Optimization Cycle

PR Newswire

LONDON and NEW YORK, Nov. 13, 2020 /PRNewswire/ — TriOptima, a leading infrastructure service that helps to lower costs and to mitigate risk in OTC derivatives markets, announced the completion of its first triBalance FX cycle optimizing exposures for clients who calculate their leverage ratio capital requirements under the Standardized Approach for Measuring Counterparty Credit Risk (SA-CCR). Bilateral and cleared initial margin exposures were simultaneously optimized in the FX cycle that took place on October 29, 2020.

The triBalance service has been available for cleared and bilateral transactions since 2017. triBalance generates a customized set of new risk reducing transactions that allow clients to redistribute bilateral exposures within TriOptima’s multilateral network to manage counterparty credit risk.

“TriOptima is preparing FX clients for the new SA-CCR requirements that are currently being phased in across the major jurisdictions before the end of next year,” said Philip Junod, Senior Director, triReduce and triBalance Business Management. “Being the first to include the all-in net exposures in our optimization cycle helps us support our network of thirty banks, the largest multilateral network in the industry, as they seek to reduce their counterparty risk and manage their capital exposures.”

TriOptima runs weekly FX optimization cycles for 30 currency pairs and will include SA-CCR optimization in all future cycles.

TriOptima is a part of CME Group. For more information on TriOptima offerings, visit here.

About CME Group
As the world’s leading and most diverse derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex® platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing.  With a range of pre- and post-trade products and services underpinning the entire lifecycle of a trade, CME Group also offers optimization and reconciliation services through TriOptima, and trade processing services through Traiana.

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and, E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec, EBS, TriOptima, and Traiana are trademarks of BrokerTec Europe LTD, EBS Group LTD, TriOptima AB, and Traiana, Inc., respectively.  Dow Jones, Dow Jones Industrial Average, S&P 500 and S&P are service and/or trademarks of Dow Jones Trademark Holdings LLC, Standard & Poor’s Financial Services LLC and S&P/Dow Jones Indices LLC, as the case may be, and have been licensed for use by Chicago Mercantile Exchange Inc.  All other trademarks are the property of their respective owners. 

CME-G

Cision View original content:http://www.prnewswire.com/news-releases/tribalance-completes-first-fx-sa-ccr-optimization-cycle-301172480.html

SOURCE CME Group

Posted on

Positive Results from RhoVac’s Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer

PR Newswire

STOCKHOLM, Nov. 13, 2020 /PRNewswire/ — RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac’s drug candidate RV001 was safe and well tolerated, and that a long-lasting immune response could be generated in the vast majority of patients. In the patients who had a measurable PSA when they started the study, a markedly increased PSA doubling time was seen, indicating cancer-specific effectiveness.

The Phase I / II clinical study included 22 patients who had previously undergone radical prostatectomy. These patients received injections subcutaneously with RV001 for a total of 30 weeks. Safety and vaccine-specific immune responses were evaluated during treatment and thereafter for a follow-up period of 13 months. As previously reported, RV001 was well tolerated, and no serious treatment-related adverse reactions were observed. Regarding immunological effects, most patients developed a strong CD4 T-cell response that lasted for at least ten months after the last injection of treatment. The RV001-induced T cells were polyfunctional and, according to the authors of the article, well equipped for anti-tumour effect. Serum levels of prostate-specific antigen (PSA) were also monitored before and after treatment and PSA doubling time was calculated. This is considered an important predictive factor for metastasis and recurrence in cancer. In those patients who had measurable PSA at the start of the study, a markedly prolonged PSA doubling time was seen after treatment. For further details, please refer to the publication – see link below.

RhoVac’s drug candidate, RV001, is based on a well-proven method for antigen-based T-cell activation (cancer vaccination) but adds two new components to the concept. On the one hand, the use of a new target protein, RhoC, which is a protein that is overexpressed in metastatic cancer cells of various tissue types. As the overexpression of RhoC is not tissue-specific, the treatment concept could therefore work in many different types of cancer. Initially, however, RhoVac intends to confirm that it works in prostate cancer. The other new parameter in RhoVac’s drug concept is the treatment paradigm. Previous developmental cancer vaccines have been targeted at late-stage cancer treatment, but RhoVac has done the opposite and targeted its drug candidate at early treatment, after surgery or radiation of the primary tumour, to delay or even prevent the formation of metastases.

“The study met both the primary and secondary endpoints, demonstrating an excellent safety and tolerability profile, and also that the vaccine developed with RhoC as the target protein induced a potent and long-lasting T cell immunity in the majority of patients. Based on these results, we believe that vaccination with RhoC as the target protein, after initial treatment against the primary tumour, can potentially delay or prevent recurrence and metastasis. The next step is to conduct further clinical trials to see if the substantial increase in PSA doubling time can be confirmed in a larger patient group”, says Klaus Brasso, Scientific Advisor to RhoVac and Principal Investigator in the study.

Such a major trial is already well underway. A clinical phase IIb study that will include ca. 180 patients is currently ongoing in Europe (Denmark, Sweden, Finland, Germany, Belgium and the United Kingdom) and in the United States. The study is planned to be completed in early 2022 and it aims to produce results that show a solid clinical “proof of concept”.

RhoVac’s CEO, Anders Månsson, comments: “We are extremely pleased that the detailed analysis of the results of our Phase I/II study has now been published. This will for sure attract attention in immuno-oncology in general, and in the field of prostate cancer specifically, all around the world.”

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-11-202009:35 CET.

For further information, please contact:

Anders Månsson – CEO, RhoVac AB
Phone number: +46 73-751 72 78
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/rhovac/r/positive-results-from-rhovac-s-clinical-phase-i-ii-study-published-in-journal-of-immunotherapy-of-ca,c3236680

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/positive-results-from-rhovacs-clinical-phase-iii-study-published-in-journal-of-immunotherapy-of-cancer-301172624.html

SOURCE RhoVac

Posted on

Infosys Positioned as a Leader in the Everest Group PEAK Matrix® for Cloud-native Application Development Service Providers 2020

PR Newswire

BENGALURU, India, Nov. 13, 2020 /PRNewswire/ — Infosys (NYSE: INFY), the global leader in next-generation digital services and consulting, today announced that it has been positioned as a Leader in Everest Group’s PEAK Matrix® for Cloud-native Application Development Service Providers 2020. Infosys was recognized for its ability to help organizations augment their digital capabilities, modernize their core systems, and deliver design-led experiences in an agile manner. Backed by deep domain expertise and experience, Infosys leverages platforms such as Infosys PolyCloud Platform and Infosys Cloud Native Development Platform, part of Infosys Cobalt, to simplify and accelerate cloud native journey for its clients.

Infosys Logo

Everest Group assessed 21 leading service providers through a multi-phased research and analysis process for their vision and capabilities in the cloud-native applications development space. Infosys’ cloud-native application development services include API, microservices, PaaS, observability, security, and DevSecOps.

The key highlights of the report include:

  • Design thinking approach and joint workshops with clients that have helped build and demonstrate POCs, thus, fostering client confidence
  • Mature set of tools and accelerators that enable predictability and consistency in its cloud-native engagements
  • Strong pool of domain experts across industry verticals, which enables it to contextualize cloud-native solutions with a better understanding of clients’ businesses
  • Infosys’ upskilling initiatives that help provide consistent and quality delivery teams in cloud-native engagements
  • Extensive partnership with ISVs and cloud service providers to develop joint solutions and enhanced service offerings for clients

“Rapidly evolving market conditions have put unprecedented pressure on enterprises to differentiate themselves and find more agile, scalable, and cost-effective means to develop applications. In response, they are increasingly relying on cloud-native development,” said Alisha Mittal, Practice Director, Everest Group. “Infosys is enabling its clients to develop resilient cloud-native applications leveraging Infosys Cobalt, a set of services, solutions, and platforms for enterprises to accelerate their cloud journey. Infosys’ clients also appreciate its talent initiatives, design thinking approach, and domain expertise across industry verticals.”

“Cloud native applications and technologies are the way forward to drive innovation, resilience and deliver well-recognized business value to customers. It is an ideal approach for enterprises that are looking to build and run responsive, scalable, and fault-agnostic apps across public, private, or hybrid clouds,” said Shaji Mathew, Executive Vice President, Infosys. “Our positioning as a Leader in the report validates our deep domain knowledge backed by offerings from Infosys Cobalt to contextualize cloud-native solutions specific to our clients’ businesses across industry verticals.”

A complimentary custom copy of Everest Group PEAK Matrix® for Cloud-native Application Development Service Providers 2020 can be accessed here.

About Infosys

Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With nearly four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.

Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2020. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

 

Cision View original content:http://www.prnewswire.com/news-releases/infosys-positioned-as-a-leader-in-the-everest-group-peak-matrix-for-cloud-native-application-development-service-providers-2020-301172623.html

SOURCE Infosys

Posted on

AAK to build a Plant-based Foods Global Center of Excellence

PR Newswire

KARLSHAMN, Sweden, Nov. 13, 2020 /PRNewswire/ — In line with its strategic direction, AAK AB (publ.) has decided to establish a Plant-based Foods Global Center of Excellence on the company’s premises in Zaandijk, the Netherlands. AAK has been operating here for decades and this strategic location, near Amsterdam in one of Europe’s largest food and agribusiness economies, offers proximity to many customers and industry peers as well as the nearby `Wageningen Food Valley’.

“Investing in this Plant-based Foods Global Center of Excellence reaffirms our commitment to grow our presence in this dynamic and fast-paced category”, said Johan Westman, President and CEO, AAK Group. “Acting as a knowledge center for our plant-based activities, we will develop and showcase our plant-based innovations to support customers across the world.”

To meet the fast-growing demand for plant-based foods, AAK last year launched its AkoPlanet™ by AAK portfolio with tailor-made vegetable oil and fat solutions for food and beverage manufacturers developing plant-based meat and dairy products for the retail and foodservice channels. With the establishment of the Global Center of Excellence, AAK further strengthens its capabilities for plant-based foods.

The three-story state-of-the-art center showcasing AAK’s co-development process will feature two pilot plants, an analytical laboratory, a customer experience kitchen, and a sensory suite all under one AAK roof, allowing customers to bring great-tasting food and beverages to market faster and with confidence.  

“The long-term outlook for plant-based foods is strong with sales growth outpacing that of other foods”, said Niall Sands, President Plant-based Foods at AAK. “This development is driven by several factors, among them a growth in flexitarianism, an increased focus on health and well-being, and sustainability and climate concerns among many consumers.”

The center is expected to be operational by the end of 2021.

For further information, please contact:

Niall Sands

President Plant-based Foods
Mobile: +44 7814 225 115
E-mail: [email protected]  

Fredrik Nilsson
CFO
Mobile: +46 708 95 22 21
E-mail: [email protected]

The information was submitted for publication at 9:00 a.m. CET on November 13, 2020.

AAK is a leading provider of value-adding vegetable oils & fats. Our expertise in lipid technology within foods and special nutrition applications, our wide range of raw materials and our broad process capabilities enable us to develop innovative and value-adding solutions across many industries – Chocolate & Confectionery, Bakery, Dairy, Plant-based Foods, Special Nutrition, Foodservice, Personal Care, and more. AAK’s proven expertise is based on more than 140 years of experience within oils & fats. Our unique co-development approach brings our customers’ skills and know-how together with our own capabilities and mindset for lasting results. Listed on Nasdaq Stockholm and with our headquarters in Malmö, Sweden, AAK has more than 20 different production facilities, sales offices in more than 25 countries and more than 3,900 employees. We are AAK – The Co-Development Company.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aak-ab/r/aak-to-build-a-plant-based-foods-global-center-of-excellence,c3236604

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/aak-to-build-a-plant-based-foods-global-center-of-excellence-301172616.html

SOURCE AAK AB

Posted on

Victory Square Technologies Portfolio Company’s Leishmaniasis Rapid Test Receives Brazilian MAPA Approval for Sale & Use for the Country of Brazil and Enters into a Sales & Distribution Contract with Ecodiagnostica of Brazil

  • Victory Square Health’s
    Leishmaniasis Rapid Test
    received Brazilian MAPA approval for sale and usage in Brazil and export to Mercosur Countries in Central and South America
  • Leishmaniasis is a parasitic disease that affects humans and canines in Southern Europe, Central America, South America, Mexico and the Middle East
  • About 4 to 12 million people are currently infected


    [4]




    [5]


    in some 98 countries.


    [3]


    About 2 million new cases


    [3]


    occur annually that if undetected and untreated can cause disabilities and death.
  • About 200 million people in Asia, Africa, South and Central America, and southern Europe live in areas where the disease is common.


    [3]




    [11]
  • The Company has already received a sales order from
    Ecodiagnostica
    of Brazil for
    the
    newly approved Leishmaniasis Rapid Test

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc./Safetest (“VS Health” or the “Company”) – a portfolio company of Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it was granted approval by the Brazilian Ministry of Agriculture, Livestock, and Food Supply (MAPA) to commence marketing, sales and distribution for its Leishmaniasis Rapid Test in Brazil and export to Mercosur Countries (Argentina, Paraguay, Uruguay, and Venezuela) in Central and South America. The Company entered into a sales & distribution contract and formal partnership for the Leishmaniasis test with Ecodiagnostica of Brazil.

Leishmaniasis, is one of the world’s most neglected diseases and VS Health is strategically positioned to address this unmet need for quick and reliable testing.

Leishmaniasis is a parasitic disease that affects humans and canines in Southern Europe, Central America, South America, Mexico and the Middle East. About 4 to 12 million people are currently infected[4][5] in some 98 countries.[3] About 2 million new cases[3] occur annually that if undetected and untreated can cause disabilities and death. About 200 million people in Asia, Africa, South and Central America, and southern Europe live in areas where the disease is common.[3][11]

VS Health has developed and validated the clinical performance of its Leishmaniasis diagnostic test with a results that exceeds currently available tests with greater sensitivity and specificity in correctly diagnosing Leishmaniasis both in humans and canines with a sensitivity of 93.2% and specificity of a leading 91.3%.

The Company is pleased to have entered into a partnership, sales and distribution contract with Ecodiagnostica of Brazil for the sale of the Leishmaniasis test for South America. Ecodiagnostica (http://ecodiagnostica.com.br) manufactures and distributes products for the market of human diagnosis, veterinary, and food safety. Founded in 2012, Ecodiagnostica is based in Nova Lima, Brazil and has extensive sales and distribution networks across South America and beyond. Ecodiagnostica has placed an initial order of the VSH Leishmaniasis test at time of release.

“I am very pleased to announce our latest approval for another one of our tests in partnership with Ecodiagnostica. Our Leishmaniasis test is just one of many tests currently approved or in our development pipeline. Our global distribution and sales network has grown exponentially with our numerous approvals of our Safetest Covid-19 testing products. These new avenues and new partnership agreements will provide this test and others with easy access to key markets,” said Felipe Peixoto, CEO of Victory Square Health.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.


Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Check out VictorySquare.com and sign up to VST’s official newsletter at www.VictorySquare.com/newsletter.

Reference (1)
WHO Expert Committee. Control of the leishmaniasis: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 2010; 22-26 March. WHO Technical Report Series; 949:1-186. Available from: http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf

Reference (2)
PARASITOLOGY – CHAPTER TWO BLOOD AND TISSUE PROTOZOA PART 1 TRYPANOSOMIASIS AND LEISHMANIASIS
Dr Abdul Ghaffar Professor Emeritus University of South Carolina http://www.microbiologybook.org

On behalf of the board,

Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios
Email: [email protected]
Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director
Email: [email protected]
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth. The result: rapid scale-up and monetization, with a solid track record of public and private exits.

VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups
VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors
VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they’re unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we’re able to provide strong and stable returns while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Posted on

Arçelik A.Ş. and LG Electronics Inc settle patent disputes

PR Newswire

ISTANBUL, Nov. 13, 2020 /PRNewswire/ — Arçelik A.Ş. and LG Electronics Inc, recently settled all patent disputes related to refrigerator ice making technology and washing machine technology. Accordingly, lawsuits in Germany, France, and Spain have been terminated. Both parties are pleased the settlement brings the lawsuits to a conclusion and will allow both parties to focus on their business. Detailed terms and conditions of the settlement remain confidential.

Arcelik_Logo


About Arçelik

With over 30,000 employees throughout the world, 12 brands (Arçelik, Beko, Grundig, Blomberg, ElektraBregenz, Arctic, Leisure, Flavel, Defy, Altus, Dawlance, Voltas Beko), sales and marketing offices in 34 countries, and 22 production facilities in 8 countries, Arçelik offers products and services in nearly 150 countries. As Europe’s second largest white goods company according to market share ranking based on quantity, Arçelik reached a consolidated turnover of 5 billion Euros in 2019. With almost 70% of its profits coming from the international markets, Arçelik is the R&D leader in Turkey – holding more than 3,000 international patent applications to date with the efforts of 1,600 researchers in 15 R&D and Design Centers in Turkey and R&D Offices across five countries.

 

Cision View original content:http://www.prnewswire.com/news-releases/arcelik-a-and-lg-electronics-inc-settle-patent-disputes-301172594.html

SOURCE Arçelik

Posted on

ZIM to Launch a new Mexico – Tampa Shuttle Service in December

PR Newswire

HAIFA, Israel, Nov. 13, 2020 /PRNewswire/ — ZIM is pleased to announce the launch of the new Mexico – Tampa shuttle service (MTS), commencing in mid-December, expanding ZIM’s regional network and providing great new options for customers in Mexico & the US.

The new MTS will deploy a 1000-TEU vessel on a weekly, fixed-day schedule between the port of Altamira, Mexico and Tampa, Florida in the US. The service will depart Altamira on Fridays and call at Tampa on Mondays.

On top of the best-in-market 3-day transit time, the new MTS offers many advantages to customers, including

  • Guaranteed space allocation and container availability (dry, reefer & special equipment)
  • Calling at ATP Terminal in Altamira to provide the most reliable quality service
  • Extended cut-off dates and quick IMO Cargo approval process
  • Door-to-door and end-to-end inland service
  • Fully dedicated ZIM-operated vessel
  • Strong, reliable & highly experienced organizations and follow-up in Mexico and the US
  • ZIM’s exceptional personal customer service combined with its advanced, easy-to-use digital tools

Yoram Dallman, ZIM VP Latin America Busines Unit, said: “The new MTS is a valuable addition to our growing regional network, strengthening our position as the fastest-growing ocean carrier in the Mexican market. MTS will enable ZIM customers to benefit from a fast, reliable connection and top-level customer service.”

About ZIM: Since 1945, ZIM has been providing creative operational and logistical solutions to customers. Over the years, ZIM has grown to become a leading force in the shipping industry by pioneering innovative technologies and expanding its vast geographical network while maintaining its tradition of excellence.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zim-to-launch-a-new-mexico—tampa-shuttle-service-in-december-301172457.html

SOURCE ZIM Integrated Shipping Services Ltd.

Posted on

BevCanna Announces $5M Above Market Unit Offering

BevCanna Announces $5M Above Market Unit Offering

Investor interest signalling confidence in the cannabis-infused beverage expert

VANCOUVER, British Columbia–(BUSINESS WIRE)–
BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC):

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005194/en/

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Emerging leader in cannabis-infused beverages BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) announced today that the Company proposes to complete a non-brokered private placement of up to 10 million units (the “Units) at an offering price of $0.50 per Unit, to raise gross proceeds of up to $5.0 million (the “Offering”).

“We’re very pleased with the show of confidence we’re seeing from prospective investors,” said John Campbell, Chief Financial Officer at BevCanna. “As we approach commercialization of our products in the Canadian market and are seeing significant progress in our U.S. cannabidiol and natural products strategy, we will use the funds to accelerate our cannabis and traditional CPG strategies in both markets. This will further solidify our leadership position within the North American beverage and natural products landscape.”

The proceeds of the Offering will be used to provide working capital support for:

  • Expansion of the Company’s Canadian cannabis operations in anticipation of receipt of its Health Canada issued Standard Processing License, and the subsequent commercialization of BevCanna’s house brand and white-label client products throughout Canada
  • Continued growth of Pure Therapy, BevCanna’s U.S. nutraceutical and hemp-CBD e-commerce platform
  • Progression of the Company’s retail commercialization strategy for its house brand beverages
  • Evaluation of prospective M&A opportunities

The Offering

Each Unit will consist of one (1) common share of the Company and one (1) share purchase warrant (the “Warrants”). Each Warrant will be exercisable to acquire one additional common share at an exercise price of $0.75 per share for a period of two (2) years from the date of closing of the Offering. The terms of the Offering are subject to acceptance of the Canadian Securities Exchange.

There is no minimum aggregate proceeds amount that is required to close the Offering. All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance in accordance with applicable securities legislation. The Offering will be conducted under available exemptions from the prospectus requirements of applicable securities legislation. Qualifying subscribers who wish to participate in the Offering should contact the Company at the investor relations contact information set forth below.

None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

About BevCanna Enterprises Inc.

BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) develops and manufactures cannabinoid–infused beverages and consumer products for in–house brands and white label clients. With decades of experience creating, branding and distributing iconic brands that have resonated with consumers on a global scale, the team demonstrates an expertise unmatched in the emerging cannabis beverage category. Based in British Columbia, Canada, BevCanna owns the exclusive rights to a pristine spring water aquifer, access to a world–class 40,000–square–foot, HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum. BevCanna also recently acquired US natural health and wellness e-commerce platform Pure Therapy. BevCanna’s vision is to be a global leader in infused innovations.

On behalf of the Board of Directors:

John Campbell, Chief Financial Officer and Chief Strategy Officer

Director, BevCanna Enterprises Inc.

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including the statements regarding: the Offering, including its terms and the completion thereof, the proceeds to be raised pursuant to the Offering and the intended use of the proceeds; and other statements regarding the business plans of the Company.

Forward-looking statements are based on certain assumptions regarding the completion of the Offering; issuances of licenses by Health Canada to the Company under the Cannabis Act; future positive legislative, tax and regulatory developments with respect to cannabis; a continued high regulatory barrier entry for cannabis-infused beverages; successful and timely commercialization of the company’s products; successful and timely negotiation of various agreements; and expectations with respect to the future growth of recreational cannabis products. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. The assumptions of the Company, although considered reasonable by it at the time of preparation, may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation: the inability of the Company to complete the Offering at all or on the terms announced; the Company not receiving all necessary approvals in respect of the Offering; use of proceeds from the Offering differing from the proposed uses; the Company not being issued licenses by Health Canada; risks associated with general economic conditions; risks associated with climate and agriculture; changes in consumer preferences; adverse industry events; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of the Company which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

For media enquiries or interviews, please contact:

Wynn Theriault, Thirty Dash Communications

416-710-3370

[email protected]

For investor inquiries, please contact:

Luca Leone, BevCanna Enterprises Inc.

604-880-6618

[email protected]

KEYWORDS: North America United States Europe Germany Canada

INDUSTRY KEYWORDS: Food/Beverage Alternative Medicine Health Retail Specialty

MEDIA:

Posted on

Eaton Partners Acts as Exclusive Placement Agent for Arrow Global

€1.7 Billion of Capital Secured In Largest First-Time European Private Market Fundraise of 2020

ROWAYTON, Conn. & LONDON, Nov. 13, 2020 (GLOBE NEWSWIRE) — Eaton Partners, one of the largest capital placement agents and fund advisory firms and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), is pleased to have acted as exclusive placement agent for Arrow Global Group’s (“Arrow Global”) inaugural fund, Arrow Credit Opportunities SCSp (the “Fund”).

The Fund announced a final close of €1.7 billion in capital commitments, comprising multiple investment vehicles, including a fund and a co-investment program. This is the largest first-time European private market fund closed in 2020 and is among the largest European first-time credit funds ever raised. The Fund received strong support from some of the largest and most sophisticated global investors from diverse sectors and geographies, including the U.S., Netherlands, Canada, Switzerland, Germany, Italy, the Nordics, and Asia. The Fund will invest in selective European credit opportunities, leveraging the pan-European expertise of Arrow Global to offer investors attractive access to specialist and high-return asset classes.

Arrow Global is a leading European investor and alternative asset manager specialising in non-performing and non-core assets. Arrow identifies, acquires, and manages secured and unsecured loan and real estate portfolios from, and on behalf, of financial institutions, such as banks, institutional fund investors, and specialist lenders. The Fund will give investors access to opportunities in the already attractive non-performing loan (NPL) market, which is at the epicenter of recent economic dislocation.

“We are beyond thrilled to have worked with Arrow Global, a public company, to raise a private fund and ultimately help build a new asset management business,” said Steve Eaton, Co-Head of EMEA at Eaton Partners. “The fact that we have collectively been able to raise a record amount of capital in a challenging fundraising environment is a testament to Arrow’s leading platform and long-term vision and demonstrates strong investor appetite for unique and differentiated strategies, like those found in the European NPL market.”

“This fundraise represents a pivotal moment in Arrow’s evolution into an alternative asset manager,” added Ryan Still, Director at Eaton Partners. “This evolution owes much of its success to the market-leading loan origination, servicing, and collection business Zach Lewy and team have built over the last 15 years. We congratulate everyone at Arrow Global and wish them continued success.”

“Thank you to the Eaton Partners team for your continued support, energy, and commitment to our fundraise,” said Zach Lewy, Founder and Chief Investment Officer at Arrow Global. “I’d additionally like to thank our clients and partners who have invested in Arrow’s success. The Fund marks an exciting new chapter for the business and means we are well placed to invest into a large and growing market.”

About Eaton Partners

Eaton Partners, a Stifel Company, is one of the world’s largest capital placement agents and fund advisory firms, having raised more than $140 billion across more than 140 highly differentiated alternative investment funds and offerings. Founded in 1983, Eaton advises and raises institutional capital for investment managers across alternative strategies – private equity, private credit, real assets, real estate, and hedge funds/public market – in both the primary and secondary markets. Eaton Partners maintains offices and operates throughout North America, Europe, and Asia.

Eaton Partners is a division of Stifel, Nicolaus & Company, Incorporated, Member SIPC and NYSE. Eaton Partners subsidiary Eaton Partners (UK) LLP is authorized and regulated by the Financial Conduct Authority (FCA). Eaton Partners subsidiary Eaton Partners Advisors (HK) Limited is approved as a Type 1-licensed company under the Securities and Futures Commission (SFC) in Hong Kong. Eaton Partners and the Eaton Partners logo are trademarks of Eaton Partners, LLC, a limited liability company. ® Eaton Partners, 2020.

About
Arrow Global

Established in 2005, Arrow Global is a European investor and alternative asset manager specialising in non-performing and non-core assets. Arrow identifies, acquires and manages secured and unsecured loan and real estate portfolios from and on behalf of financial institutions, such as banks, institutional fund investors and specialist lenders. Arrow plays an active role in helping financial institutions reduce their balance sheets and recapitalise in order to increase mainstream lending. By purchasing and managing non-performing loans and other non-core assets, Arrow provides valuable capital and expertise to a growing European market. Arrow is a regulated business in all five of its European markets. Arrow invests in this asset class through its fund management business as well as directly and generates revenues from managing and servicing assets on behalf of third parties.

About
Stifel

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC and Century Securities Associates, Inc. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities. Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.

Media Contact
s

Neil Shapiro, +1 (212) 271-3447
[email protected]

Jeff Preis, +1 (212) 271-3749
[email protected]